THE PHARMACOLOGICAL DEVELOPMENT OF IPW-5371 FUMARATE AS A RADIATION MEDICAL COUNTERMEASURE FOR THE TREATMENT OF DELAYED RADIATION LUNG INJURY UNDER THE FDA ANIMAL RULE

Abstract

This proposal, using partial body irradiation (PBI) animal models to study the delayed effects of acute radiation exposure (DEARE) on survival due to multi-organ injury, including the lungs. The proposal is focused on supporting the critical path for FDA approval of an Innovation Pathways, small molecule TGFβ Receptor-1 kinase inhibitor MCM. Under the guidance criteria of the FDA “Animal Rule” (AR).

Key facts

NIH application ID

11111142

Project number

75N93023C00014-P00003-9999-1

Recipient

INNOVATION PATHWAYS, LLC

Principal Investigator

BARRY HART

Activity code

N01

Funding institute

NIH

Fiscal year

2024

Award amount

$1,499,864

Award type

—

Project period

2023-07-01 → 2025-06-30